A new compact epigenetic editor durably silences genes in the brain by recruiting the body’s own enzymes, offering a safer and more effective approach to treating neurodegenerative diseases.
June 2024 – Science
Key takeaways
- A safer gene-silencing breakthrough: The CHARM system uses a compact, non-enzymatic editor that recruits the body’s own methylation machinery to silence disease-causing genes in the brain, reducing the risks of off-target effects, immune responses, and toxicity typically seen with CRISPR-based tools
- Long-lasting impact with fewer treatments: CHARMs achieve sustained gene silencing for up to 13 weeks in the brain following a single dose, potentially lowering the need for repeated invasive treatments and offering a more durable solution for chronic neurodegenerative conditions
- Designed for precision and brain delivery: By replacing bulky CRISPR proteins with smaller zinc finger motifs, this new editor fits within a single viral vector, enabling efficient delivery to the brain—a critical advancement for targeting hard-to-reach neurological tissue
- Built-in self-regulation for added safety: CHARMs can be programmed to silence their own expression after delivering their therapeutic effect, providing an inbuilt mechanism to reduce long-term risks and fine-tune the duration of gene silencing without ongoing exposure
Read the article at: Whittaker, Madelynn N., and Kiran Musunuru. “An Epigenetic Editor to Silence Genes.” Science, vol. 384, no. 6703, 2024, doi:10.1126/science.adq3334.
